Abstract: Method for making a Cannabinoid molecule bath bomb by first etching the surface of at least one of ?9 Tetrahydrocannabinol molecule and Cannabidiol molecule. The etched Cannabinoid molecule is then combined with Sodium Bicarbonate, Citric acid, Magnesium Chloride, and a viscous binder. Once the ingredients have been combined the resulting mixture is dried to form a Cannabinoid molecule bath bomb.

Abstract: An oil-in-water emulsified sunblock cosmetic has excellent feeling when used and maintains a high ultraviolet-ray protective effect even upon contact with water or sweat. The oil-in-water emulsified sunblock cosmetic contains an (A) ultraviolet-ray protective agent and a (B) fatty acid forming a solid at room temperature, the cosmetic is characterized in that 51% or less of the fatty acid is neutralized, and the formulation ratio ((A)/(B) of the (A) ultraviolet-ray protective agent to the (B) fatty acid is in the range of at least 0.1 and less than 10.0. The cosmetic exhibits the unprecedented and surprising property of contact with water causing an improvement to the ultraviolet-ray protective ability. It is preferable for the cosmetic to contain an (C) oily component having IOB of 0.5 or higher.

Abstract: Anhydrous topical compositions containing a solid or hollow particle ranging from 0.001 to 200 microns in diameter coated with Indium Tin Oxide (“ITO”) and methods for protecting skin against IR (infrared) radiation by topically applying the anhydrous compositions.

Abstract: A sunscreen cosmetic eliminates instability of a dibenzoylmethane derivative that is a UVA absorbing-agent, which exhibits excellent ultraviolet radiation protection performance across a wide wavelength region from UVA to UVB, and which exhibits excellent light resistance, is stable over time, and does not suffer from discoloration or crystal precipitation, and with which unnatural whiteness does not occur. A sunscreen cosmetic contains (a) a dibenzoylmethane derivative and (b) a powder that is surface-hydrophobized by means of treatment with a metal soap comprising a higher fatty acid and an alkaline earth metal or a combined treatment involving the use of a higher fatty acid and an alkaline earth metal hydroxide. The alkaline earth metal is preferably calcium or magnesium, and the higher fatty acid is preferably isostearic acid.

Abstract: A cosmetic antiperspirant composition, i.e., a perspiration-inhibiting or sweat-inhibiting composition, which comprises at least one active antiperspirant ingredient selected from the group consisting of hydroxycarboxylic acid, hydroxycarboxylic salt, and mixtures thereof.

Abstract: Use of a hair treatment composition comprising a lactone, a disaccharide, an inorganic salt and an organic acid or salt thereof, having a pH in the range of from 3 to 6.5, in the treatment of hair, to repair damage to hair protein, preferably to increase the denaturation temperature of the internal protein of hair.

Abstract: A skin care composition comprising one or more alpha hydroxy acids, one or more salts of alpha hydroxyl acids, one or more tretinoin, retinols or retinol-like compounds, and niacinamide or hydroquinone. A method of treating skin with the skin care composition comprising the steps of a) cleaning the skin; and b) applying the skin care composition to the skin.

Abstract: A method of correcting the visible and microscopic signs of Dermatoheliosis (chronic ultraviolet light-damaged human skin) and its various clinical manifestations (wrinkling, sagging, fragility, melasma, Poikiloderma of Civatte, solar lentigines, and senile purpura) and also Androgenetic Alopecia and Seborrheic Keratoses consists of the administration of fatty acid derivatives capable of inhibiting mast cells and the mediators they release that cause local tissue damage. These fatty acid derivatives include palmitoylethanolamide (PEA) and related cannabinomimetic compounds and adelmidrol and related Autacoid Local Injury Antagonist amides (ALIAmides) which are administered orally or applied topically. Adelmidrol, the best absorbed topically, is applied in a concentration of between 1% and 10% by volume, with a preferred concentration of about 5% by volume.

Abstract: This invention relates to oral care compositions comprising arginine or lysine, zinc citrate and zinc oxide, fluoride source, and a silica abrasive which exhibits an acid pH when measured as an aqueous slurry as well as to methods of using and of making these compositions.

Abstract: A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.

Abstract: A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.

Abstract: An oral care formulation and method for removing tartar and plaque from the teeth, gums, and oral cavity is disclosed. The oral care formulation can take the form of a toothpaste, gel, wash, rinse, soak, spray, chewing gum, dental floss, or other suitable delivery system, containing a therapeutically effective amount of dimethyl isosorbide (DMI) (or equivalent or analog thereof) and chlorine dioxide (ClO2) for removal of tartar and plaque.

Abstract: The invention relates to a cosmetic process for caring for or making up keratin materials, comprising either the topical application to the keratin materials of an (extemporaneous) anhydrous mixture of a cosmetic composition comprising a maleic anhydride acrylic polymer and of an amino alkoxysilane compound (I); or the sequential application to the keratin materials of an anhydrous cosmetic composition comprising a maleic anhydride acrylic polymer and of an amino alkoxysilane compound (I), wherein said maleic anhydride acrylic polymer is obtained by polymerization of: (a) 50% to 90% by weight, relative to the total weight of monomers, of isobornyl (meth)acrylate (b) 1% to 50% by weight of maleic anhydride (c) 0% to 49% by weight of additional (meth)acrylate monomer; said amino alkoxysilane having the formula (I): R—NH—R1Si(OR2)z(R3)x??(I) in which: R1 is a C1-C20 hydrocarbon-based divalent group, R=H or a C1-C4 alkyl group, R2 and R3 represent an alkyl group comprising from 1 to 6 carbon atoms; z d

Abstract: A method in accordance with a particular embodiment of the present invention includes increasing a concentration of a modified or unmodified saccharide within a subject's skin, applying an applicator to the subject's skin, and cooling the subject's skin via a heat-transfer surface of the applicator. The saccharide within the subject's skin can enhance a resistance of at least some cells within the subject's skin to damage associated with the cooling. A corresponding system includes the applicator, the saccharide, and an energy-delivery device. The energy-delivery device can be configured to apply ultrasound, optical, thermal, or another type of energy to the subject's skin to drive the saccharide into the subject's skin. The system can also include a penetration enhancer configured to enhance penetration of the saccharide into the subject's skin. The penetration enhancer can be applied with the saccharide or separately.

Abstract: A bio-cellulose slurry is provided. The bio-cellulose slurry comprises the following components: bio-cellulose; a backbone fiber selected from the group consisting of rayon fibers, polyethylene terephthalate (PET) fibers, nylon fibers and combinations thereof; an adhesive fiber selected from polyethylene composite fibers; an adhesion promoter selected from the group consisting of polyamides, low density polyethylenes and combinations thereof; a humectant selected from polyols; and a dispersion medium. The bio-cellulose slurry is useful in manufacturing a dry bio-cellulose material with outstanding water absorption rate and wet strength.

Abstract: The present disclosure relates to multi-functional anti-microbial polymers comprising a first monomer having a polymerizable cyclic aromatic moiety which forms part of the backbone of the polymer and a second monomer having an ethylenically unsaturated monomer having a double or triple bond and a quaternary ammonium or quaternary phosphonium moiety.

Abstract: The present disclosure provides compositions comprising decontaminating compounds, and pharmaceutically acceptable salts thereof and methods of treating or preventing a contamination in a mammal, in particular, the composition can include a mixture of polyvinyl acetate and povidone, a cobloek polymer of ethylene oxide and propylene oxide, a polyvinyl alcohol, or combinations thereof, and an aqueous suspending agent.

Abstract: The present invention relates to a composition for application to the human and animal body or to plants, comprising at least one active ingredient and/or fragrance, comprising a polyurethane urea which is dissolved in a solvent or solvent mixture, the solvent consisting of one or more monohydroxy-functional alcohols, or a solvent mixture consisting of organic solvents, which contains ?50% by weight, based on the total mass of the solvent mixture, of at least one monohydroxy-functional alcohol, is used. The invention additionally embraces the composition for treating the human or animal body, the use of the composition to coat substrates, the substrates not being the human or animal body, and the use of the composition for application to the human or animal body, the active ingredient not having a therapeutic effect.

Abstract: The present disclosure relates to methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, by application of one or a combination of natural compounds or extracts that stimulate MAGP-1 expression and which improves the appearance of aged and/or photodamaged skin. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof in an amount effective to improve the condition and aesthetic appearance of skin.

Abstract: The present invention relates to a composition containing extracellular vesicles derived from plant juice, wherein the extracellular vesicles have excellent skin condition-improving effects such as skin whitening, moisturizing and wrinkle reducing effects and exhibits an excellent effect of preventing hair loss by promotion of hair growth and regrowth, and the like.

Abstract: Infusion from a mixture of species of the Sideritis plant for topical cutaneous or other uses formed by mixing the plants of the Sideritis family with the names Sideritis perfoliata/Sideritis scardica/Sideritis raeseri at proportions by weight from 70/25/5 to 40/50/10, with deionised water as extraction solvent, at a proportion by weight of the mixture of the Sideritis plants to the solvent from 0.01% to 10% and used either as such for topical cutaneous use, or as a component of cosmetic or cosmeceutical products at a proportion by weight from 0.01% to 80% in the produced final product, which is produced by an extraction device in which the pressure and temperature are controlled where the plants are placed in comminuted form and the solvent is added and the extraction procedure takes place under a pressure of 0 bar to 10 bar at 37° C. to 98° C., for from one to thirty minutes.

Abstract: The present document describes an oral care composition comprising a cuttlefish bone powder, comprising particles having more than 95% (w/w) calcium carbonate content, and a particle size of from about 60 microns to about 75 microns, and a suitable carrier, and uses of said composition for oral hygiene.

Abstract: Convenient, inexpensive and portable effervescent tablets that the consumer can add to water to generate hydrogen-rich water just prior to drinking. The effervescent tablets include a base metal and an edible acid that, within about 5-10 minutes of mixing, generate a palatable aqueous solution having about 0.8 mM to about 3 mM hydrogen and a pH of 8-10.

Abstract: The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.

Abstract: The present disclosure is directed to injectable formulations that include biodegradable polymers based on trimethylene carbonate (TMC) with mole fractions of polylactic acid (PLA) and/or polyglycolic acid (PGA) that are used to deliver a bioactive agent to a targeted site. Excipients such as polyethylene glycol (PEG) may be added to the formulations to reduce the injection force and/or to modulate the release of the bioactive agent. Suitable biodegradable polymers for use in the injectable formulations include D,L-PLA:TMC, D-PLA:TMC, L-PLA:TMC, TMC:PLA:PGA and variations thereof. Additionally, copolymers of TMC and PLA and terpolymers of TMC:PLA:PGA may be formed into nanoparticles and delivered to the target site with an injectable crosslinkable polyethylene glycol system. In at least one embodiment, the injectable formulations are used to treat ocular diseases.

Abstract: Compositions and methods for treating hyperemia and symptoms in pinguecula and pseudopteryigium are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Abstract: Compositions and methods for treating hyperemia and symptoms in pterygium patients are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

Abstract: The invention provides methods for administering lentiviral vectors to the respiratory system of a patient to treat a disease.

Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse; the enema for rectal application described above, in which a dose of budesonide is 2.0 mg per dose; the enema for rectal application according to any one of the above, which is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; the enema for rectal application according to any one of the above, which has a foamy shape or a liquid shape.

Abstract: Compositions which comprise a liposomal camptothecin and optionally liposomal fluoropyrimidine and a targeted antitumor agent are useful in achieving enhanced therapeutic effects when combinations of these agents are administered.

Abstract: Disclosed is a method of producing a vesicle containing a metallic nanoparticle that is covalently bound to at least one hydrophilic polymer and at least one hydrophobic polymer, wherein the method involves dispersing the polymer-bound metallic nanoparticle in an organic solvent, adding an aqueous solution containing a dispersing aid to form a mixed solution, sonicating the mixed solution to form an emulsion; and removing the organic solvent from the emulsion until the vesicle forms. Using this method, the formed vesicle has a diameter of 20-150 nm, which is useful for a method of conducting photothermal therapy (PTT) for killing cells, such as cancer cells.

Abstract: The present disclosure provides a sustained-release composition including a sodium hydrosulfide and a carrier. The carrier is provided for carrying the sodium hydrosulfide with an effective amount and includes a first component and a second component. The first component includes a paraffin wax, and the second component includes a fatty alcohol, a fatty acid or a phospholipid. The present disclosure also provides a method for fabricating the sustained-release composition. The method includes providing a first solution, providing the carrier, providing a second solution, performing an oil-in-water emulsification, and cooling the emulsion. In addition, the present disclosure provides a method for treating the chronic wounds. The method includes administering an effective amount of the aforementioned sustained-release composition to a subject suffered from the chronic wounds.

Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.

Abstract: Systems and methods for fabricating ingestible pharmaceutical tablets are provided. Certain of the systems and methods described herein are capable of manufacturing tablets of different dosages without the need to fluidically connect or disconnect unit operations when switching from a tablet having a first dosage to a tablet having a second, different dosage. Certain of the systems and methods described herein are capable of manufacturing compositionally tablets, e.g., tablets with different active pharmaceutical ingredients (APIs).

Abstract: Embodiments may include a composition for oral drug delivery. The composition may include a physiologically active substance, a carrier compound, a mucoadhesive compound, and a permeation enhancer. The physiologically active substance may be transported across the stomach. The physiologically active substance may be stable and not degrade in the harsh gastric acid environment. To help protect the physiologically active substance, the physiologically active substance is mixed with the carrier. The carrier may be a liquid insoluble in the gastric acid of the stomach. The physiologically active substance may be soluble in the carrier. The mucoadhesive compound may be used to promote adsorption of the physiologically active substance to the lining of the stomach. The permeation enhancer may facilitate the transport of the physiologically active substance across the wall of the stomach.

Abstract: Materials and methods for preparing a payload-containing microcapsule with walls that have hexahydrotriazine (HT) and/or hemiaminal (HA) structures are disclosed. To an HT small molecule or a HA small molecule, or a combination thereof, in a solvent is added a cross-linking agent, NH4Cl, and a copolymer. The solution is acidified, and a payload agent is added. The HT small molecule and HA small molecule may have orthogonal functionality.

Abstract: Disclosed herein are methods and compositions to treat solid tumors. In one embodiment, the method of treating a solid tumor in a patient includes administering at the tumor site a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule and administering a prodrug which is activated by cytochrome P450, wherein the prodrug is administered at least three or more cycles, and wherein each cycle comprises three consecutive daily administration.

Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.

Abstract: Improved distribution can be achieved by delivering nanoparticles possessing non-adhesive surfaces via CED in a hyperosmolar infusate solution. This delivery strategy minimizes the hindrances imposed by the brain extracellular matrix and reduces the concentration of therapeutic that is confined within perivascular spaces.

Abstract: Recently, we have introduced fibrous dosage forms that enable predictable microstructures with a greater range of pharmaceutically relevant properties. Presented herein, accordingly, are a method and an apparatus for the manufacture of such fibrous dosage forms. The method includes extruding a plasticized matrix through an exit port of an extrusion channel to form at least one plasticized fiber, and structuring said at least one plasticized fiber to a three dimensional structural network of fibers. The apparatus includes an internally hollow housing defining an extrusion channel, a conveying element for extruding a plasticized matrix in the extrusion channel through an exit port to form at least one plasticized fiber, and a unit for structuring said at least one plasticized fiber to a three dimensional structural network of fibers.

Abstract: The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

Abstract: An active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The active delivery system includes a plurality of microcells, wherein the microcells are filled with a medium including an active ingredient and charged or magnetic particles. The microcells include an opening, and the opening is spanned by a porous diffusion layer. Because the porous diffusion layer can be blocked with the charged or magnetic particles, the rate at which the active ingredient is dispensed can be controlled with an electric or magnetic field, respectively.

Abstract: An active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The active delivery system includes a plurality of microcells, wherein the microcells are filled with a medium including active molecules. The microcells include an opening, and the opening is spanned by a porous diffusion layer. The microcell arrays may be loaded with different active ingredients, thereby providing a mechanism to deliver different, or complimentary, active ingredients on demand.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-QM, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample.

Abstract: Radiation therapy or chemotherapy may cause oral mucositis. Compositions are disclosed here which prevent and/or treat oral mucositis caused by radiation therapy or chemotherapy. The compositions are also effective in treating a number of skin disorders.